复宏汉霖联手奥鸿药业推进复妥宁®商业化进程

Core Viewpoint - The collaboration between Fuhong Hanlin and Aohong Pharmaceutical aims to accelerate the commercialization process of the innovative small molecule CDK4/6 inhibitor, Fovetizumab (brand name: Fuzhening) [1] Group 1: Company Collaboration - Fuhong Hanlin has announced a partnership with Aohong Pharmaceutical to expedite the commercialization of Fuzhening [1] - Fuzhening has received approval in China for use in patients with locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer who have progressed after initial endocrine therapy [1] - Aohong Pharmaceutical developed Fuzhening, while Fuhong Hanlin holds exclusive commercialization rights in China [1]